CE Geyer

492 citations
23 papers · 262 · h-index 9

Impact in

  • Cancer Research
    • Breast Cancer Treatment Studies
    • Cancer Genomics and Diagnostics
  • Oncology
    • HER2/EGFR in Cancer Research
    • Cancer Treatment and Pharmacology

Papers in

Co-authors
Norman Wolmark (16 shared papers)EP Mamounas (13 shared papers)SM Swain (10 shared papers)Soonmyung Paik (4 shared papers)Priya Rastogi (10 shared papers)Louis Fehrenbacher (4 shared papers)J. P. Costantino (8 shared papers)Adam Brufsky (5 shared papers)
Journals
Cancer Research (17 papers)Annals of Oncology (2 papers)The Breast (1 paper)European Journal of Cancer (1 paper)European Journal of Cancer Supplements (1 paper)
Partner nations
United StatesBelgiumSwitzerland

In The Last Decade

CE Geyer

23 papers receiving 260 citations

Peers

CE Geyer
Comparison fields: 5 of 28
  • Cancer Research 148
  • Oncology 217
  • Radiology, Nuclear Medicine and Imaging 74
  • Pulmonary and Respiratory Medicine 71
  • Genetics 54
Replace SM Swain with:
SM Swain United States
Barbara Ruepp Switzerland
Arisa Nishimukai Japan
Jorianne Boers Netherlands
Danai Fimereli Belgium
Clasina M. Venema Netherlands
Jean‐Christophe Théry France
HJ Burstein United States
Lillian M. Smyth United States
Jason Mouabbi United States
CE Geyer relative to SM Swain United States SM Swain's profile →
Citations per field
00.5×1.5×2.1×
SM Swain · 1×
Citations per year

Countries citing papers authored by CE Geyer

Since Specialization
Citations

This map shows the geographic impact of CE Geyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by CE Geyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites CE Geyer more than expected).

Fields of papers citing papers by CE Geyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by CE Geyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by CE Geyer. The network helps show where CE Geyer may publish in the future.

Co-authors

The 25 scholars most cited alongside CE Geyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with CE Geyer Line = papers co-authored together CE Geyer links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC)
Cancer Research ·L. Fehrenbacher, RS Cecchini, CE Geyer, Priya Rastogi, J. P. Costantino, JN Atkins, Jonathan Polikoff, J-F Boileau, Louise Provencher, Christopher Stokoe, T Moore, A. Robidoux, Virginia F. Borges, KS Albain, SM Swain, Soonmyung Paik, EP Mamounas, Norman Wolmark
201840
2
Abstract S1-05: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42
Cancer Research ·EP Mamounas, Hanna Bandos, BC Lembersky, CE Geyer, Louis Fehrenbacher, ML Graham, SL Chia, Adam Brufsky, BT Hennessy, GS Soori, S. R. Dakil, T. E. Seay, JL Wade, EC McCarron, Soonmyung Paik, SM Swain, D. L. Wickerham, Norman Wolmark
201737
3
Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831
Cancer Research ·Edward H. Romond, VJ Suman, J-H Jeong, GW Sledge, CE Geyer, Silvana Martino, Priya Rastogi, Julie R. Gralow, SM Swain, Eric P. Winer, Gerardo Colón‐Otero, Clifford A. Hudis, Soonmyung Paik, Nancy E. Davidson, EP Mamounas, JA Zujewski, Norman Wolmark, E. González Pérez
201233
4
Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52
Cancer Research ·MF Rimawi, RS Cecchini, Priya Rastogi, CE Geyer, Louis Fehrenbacher, PJ Stella, Zoneddy Dayao, Rachel Rabinovitch, S.H. Dyar, P. Flynn, Luis Báez-Díaz, Soonmyung Paik, SM Swain, EP Mamounas, CK Osborne, Norman Wolmark
201729
5
VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
Annals of Oncology ·Andrew Tutt, John J. Garber, R.D. Gelber, Kelly‐Anne Phillips, Andrea Eisen, Oskar T. Johannsson, Priya Rastogi, Karen Cui, S-A. Im, R. Yerushalmi, Adam Brufsky, Maria Taboada, Giovanna Rossi, Greg Yothers, C Singer, Luis Fein, Niklas Loman, David Cameron, Christine Campbell, CE Geyer
202226
6
NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer.
Cancer Research ·SM Swain, Joon Jeong, CE Geyer, J. P. Costantino, ER Pajon, L. Fehrenbacher, JN Atkins, Jonathan Polikoff, V. G. Vogel, JK Erban, R. B. Livingston, EA Perez, EP Mamounas, PA Ganz, S. R. Land, Norman Wolmark
200921
7
S5-7: A Phase 2, Randomized, Open-Label, Study of Neratinib (HKI-272) vs Lapatinib Plus Capecitabine for 2nd/3rd-Line Treatment of HER2+ Locally Advanced or Metastatic Breast Cancer.
Cancer Research ·M Martín, Jacques Bonneterre, CE Geyer, Yasuaki Ito, J. Ro, I. Láng, S-B. Kim, Caroline Germa, Jennifer Vermette, M-L Vo Van, K Wang, K Wang, Ahmad Awada
201116
8
S2-3: NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis.
Cancer Research ·AHG Paterson, SJ Anderson, BC Lembersky, Louis Fehrenbacher, CI Falkson, K. King, L. Weir, Adam Brufsky, Shaker R. Dakhil, Thomas E. Lad, Luis Báez-Díaz, JR Gralow, A. Robidoux, EA Perez, Ping Zheng, CE Geyer, SM Swain, J. P. Costantino, EP Mamounas, Norman Wolmark
201114
9
Abstract S3-2: Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02)
Cancer Research ·Stefan Aebi, Shari Gelber, István Láng, SJ Anderson, A. Robidoux, M Martín, JWR Nortier, EP Mamounas, CE Geyer, Rudolf Maibach, RD Gelber, Norman Wolmark, Irene Wapnir
201210
10
Abstract OT1-1-06: A phase 3, randomized, open-label trial comparing trastuzumab emtansine and trastuzumab as adjuvant therapy for HER2-positive primary breast cancer with residual invasive tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE)
Cancer Research ·CE Geyer, Sibylle Loibl, EP Mamounas, Michael Untch, Norman Wolmark, Chiun‐Sheng Huang, Max S. Mano, Minqiao Zheng, Melanie C. Smitt, Gϋnter von Minckwitz
20138
11
PD07-08: The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy: NSABP Protocol B-40.
Cancer Research ·HD Bear, Gong Tang, Priya Rastogi, CE Geyer, André Rogatko, JN Atkins, Luis Báez-Díaz, Adam Brufsky, Mehta Rs, Louis Fehrenbacher, ER Pajon, FM Senecal, R. Gaur, RG Margolese, PT Adams, HM Gross, J. P. Costantino, SM Swain, EP Mamounas, Norman Wolmark
20116
12
NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer.
Cancer Research ·PA Ganz, S. R. Land, CE Geyer, J. P. Costantino, ER Pajon, L. Fehrenbacher, JN Atkins, JA Polikoff, V. G. Vogel, JK Erban, R. B. Livingston, EA Perez, EP Mamounas, Norman Wolmark, SM Swain
20093
13
OT1-02-07: NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2−Low Invasive Breast Cancer.
Cancer Research ·L. Fehrenbacher, J-H Jeong, Priya Rastogi, CE Geyer, Seungmok Paik, PA Ganz, S. R. Land, J. P. Costantino, SM Swain, EP Mamounas, Norman Wolmark
20113
14
Abstract GS4-02: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials
Cancer Research ·Olivia Pagani, MM Regan, GF Fleming, BA Walley, Marco Colleoni, István Láng, HL Gómez, Carlo Tondini, HJ Burstein, MP Goetz, Eva Ciruelos, Vered Stearns, Marc Debled, Silvana Martino, CE Geyer, G. Pinotti, AS Coates, Aron Goldhirsch, RD Gelber, PA Francis
20183
15
Abstract GS4-03: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial
Cancer Research ·GF Fleming, PA Francis, István Láng, Eva Ciruelos, Meritxell Bellet, H Bonnefoi, MA Climent, Lorenzo Pavesi, HJ Burstein, Silvana Martino, NE Davidson, CE Geyer, BA Walley, RE Coleman, P Kerbrat, S Buchholz, JN Ingle, Manuela Rabaglio, Marco Colleoni, MM Regan
20182
16
248TiP A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant continuation of atezolizumab/placebo (GeparDouze)
Annals of Oncology ·Sibylle Loibl, Priya Rastogi, Sabine Seiler, Christian Jackisch, Peter C. Lucas, Carsten Denkert, Andrew Poklepovic, Fernando Moreno, Eleftherios P. Mamounas, Valentina Nekljudova, Yan Lin, Norman Wolmark, CE Geyer
20202
17
P117 Exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): results of NSABP B-33
The Breast ·CE Geyer, E. Mamounas, J.-H. Jeong, Lawrence Wickerham, PA Ganz, Laura F. Hutchins, Andrew Eisen, J. Ingle, J. Costantino, Norman Wolmark
20072
18
Lapatinib plus capecitabine versus capecitabine alone for ErbB2-positive metastatic breast cancer (MBC) – Quality of Life (QOL) assessment
European Journal of Cancer Supplements ·Xingtao Zhou, Anthony C. Segreti, David Cella, David Cameron, CE Geyer, M. Amonkar, Shayna Stein, M. Walker
20082
19
Abstract PD2-1: Body mass index at diagnosis and breast cancer survival prognosis among clinical trial populations: Results from NSABP B-30, B-31, B-34, and B-38
Cancer Research ·RS Cecchini, SM Swain, J. P. Costantino, Priya Rastogi, J-H Jeong, SJ Anderson, Guannan Tang, CE Geyer, BC Lembersky, Romond Eh, A.H.G. Paterson, Norman Wolmark
20131
20
Abstract OT3-05-01: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze
Cancer Research ·CE Geyer, Sibylle Loibl, Priya Rastogi, Sabine Seiler, J. P. Costantino, VN Nekljudova, Patricia Cortazar, Peter C. Lucas, Carsten Denkert, EP Mamounas, Christian Jackisch, Norman Wolmark
20191

About CE Geyer

CE Geyer is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Genetics and Pharmacology, having authored 23 papers that have together received 262 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (17 papers), Advanced Breast Cancer Therapies (16 papers), Estrogen and related hormone effects (7 papers), Cancer Treatment and Pharmacology (6 papers), HER2/EGFR in Cancer Research (6 papers), Prostate Cancer Treatment and Research (3 papers), Colorectal Cancer Treatments and Studies (2 papers) and Bone health and treatments (1 paper). The work is most often cited by research in Cancer Research (148 citations), Oncology (217 citations), Radiology, Nuclear Medicine and Imaging (74 citations), Pulmonary and Respiratory Medicine (71 citations) and Genetics (54 citations). CE Geyer has collaborated with scholars based in United States, Belgium and Switzerland. Frequent co-authors include Norman Wolmark, EP Mamounas, SM Swain, Soonmyung Paik, Priya Rastogi, Louis Fehrenbacher, J. P. Costantino, Adam Brufsky, Jonathan Polikoff and JN Atkins. Their work appears in journals such as Cancer Research, Annals of Oncology, The Breast, European Journal of Cancer and European Journal of Cancer Supplements.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by SM SwainBreakdown of academic impact, for papers by Barbara RueppBreakdown of academic impact, for papers by Arisa NishimukaiBreakdown of academic impact, for papers by Jorianne BoersBreakdown of academic impact, for papers by Danai FimereliBreakdown of academic impact, for papers by Clasina M. VenemaBreakdown of academic impact, for papers by Jean‐Christophe ThéryBreakdown of academic impact, for papers by HJ BursteinBreakdown of academic impact, for papers by Lillian M. SmythBreakdown of academic impact, for papers by Jason Mouabbi